Bremelanotide · Vyleesi
PT-141
Label exists Melanocortin agonist
What it is
PT-141 (bremelanotide) is a cyclic melanocortin agonist. Vyleesi is the approved on-demand product for hypoactive sexual desire disorder in a specific population. Research vials are not Vyleesi.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Bremelanotide (Vyleesi) is the approved female hypoactive-desire shot from this melanocortin path.
- In plain terms: it can turn up sexual desire through the brain, not through blood-flow the way PDE5 pills do.
- Nausea and darkening/flushing are common. Research MT-2 leftovers are not Vyleesi.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Central melanocortin-receptor activity (especially MC4R) is the sexual-function story, distinct from genital-vascular PDE5 drugs.
Possible side effects / caveats
Nausea is the dose-limiting effect in the labeled product. Transient blood-pressure increase, flushing, headache, and darkening of skin/gums with repeated melanocortin exposure are documented themes. Not for uncontrolled hypertensive patients on the label.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Label (Vyleesi) | 1.75 mg | As needed SC, with use limits on the insert | Official figure for the approved drug |
| Cited research talk | 0.5–2 mg | PRN | Uncontrolled; nausea rises fast |